fluorouracil has been researched along with Left Ventricular Dysfunction in 21 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 9.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 9.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 9.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 7.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| "The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy." | 7.73 | Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. ( Bonneterre, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| "Epirubicin-based chemotherapy improves the outcome of early breast cancer (BC) patients." | 5.20 | Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. ( Aftimos, P; Ameye, L; Beauduin, M; Bejarano Hernández, S; Cornez, N; de Azambuja, E; Delhaye, F; Diaz, M; Focan, C; Lemort, M; Paesmans, M; Piccart-Gebhart, M; Shih-Li, C; Suter, T; Vandenbossche, S; Vindevoghel, A, 2015) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 5.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial." | 5.11 | Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. ( Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C, 2004) |
| "5-Fluorouracil (5-FU) is the third most common chemotherapeutic agent for treating solid cancers and the second most common to cause cardiotoxicity." | 3.91 | Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug. ( Afonso, L; Ahmed, A; Mishra, T; Shokr, M, 2019) |
| "We reported a case of large right atrial thrombus which migrated from the inferior vena cava after acute left ventricular dysfunction due to 5-Fluorouracil cardiotoxicity." | 3.74 | Right atrial thrombus from inferior vena cava after acute cardiotoxicity of 5-fluorouracil. ( Goudev, A; Kinova, E; Zlatareva, N, 2008) |
| "The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy." | 3.73 | Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. ( Bonneterre, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| "Neoadjuvant therapy for cancer of the esophagus or gastroesophageal (GE)-junction is well established." | 2.80 | Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial. ( Alexandersson von Döbeln, G; Kalman, S; Lund, M; Lundell, L; Nilsson, M; Tsai, JA; Winter, R, 2015) |
| " We evaluated the incidence of adverse events among an elderly population of trastuzumab-treated HER-2-positive breast cancer patients in adjuvant settings." | 2.77 | Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. ( Horio, A; Mizuno, T; Mukai, H; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Watanabe, T; Yamamoto, Y, 2012) |
| "Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled." | 2.76 | Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. ( Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G, 2011) |
| "A total of 180 breast cancer survivors from a potential sample of 1,176 patients were entered, 163 patients at 5 to 8 years and 17 additional patients at 10 to 13 years, with 93 longitudinal assessments of LVEF." | 2.73 | Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. ( Albain, KS; Dakhil, SR; Ganz, PA; Giguere, JK; Goodwin, JW; Hussey, MA; Hutchins, LF; Martino, S; Moinpour, CM; Unger, JM, 2008) |
| "Patients with HER2-positive operable breast cancer were randomly assigned to doxorubicin plus cyclophosphamide (AC) followed by either weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or paclitaxel plus trastuzumab then trastuzumab alone (arm C)." | 2.73 | Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. ( Dakhil, SR; Davidson, NE; Gelmon, KA; Gersh, BJ; Gralow, JR; Hudis, CA; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Sledge, GW; Suman, VJ; Winer, EP, 2008) |
| " Myriad chemotherapeutic drugs produce adverse cardiovascular effects such as arterial hypertension, heart failure, and thromboembolic events." | 2.53 | Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. ( Cadeddu, C; Deidda, M; Demurtas, L; Madeddu, C; Mercuro, G; Piras, A; Piscopo, G; Puzzoni, M; Scartozzi, M, 2016) |
| "Many types of cancer are now curable or, if not cured, becoming a chronic illness." | 2.49 | Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. ( Carver, JR; Liu, J; Manrique, C; Steingart, RM; Yadav, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mishra, T | 1 |
| Shokr, M | 1 |
| Ahmed, A | 1 |
| Afonso, L | 1 |
| Smith, SA | 1 |
| Auseon, AJ | 1 |
| Lotrionte, M | 1 |
| Cavarretta, E | 1 |
| Abbate, A | 1 |
| Mezzaroma, E | 1 |
| De Marco, E | 1 |
| Di Persio, S | 1 |
| Loperfido, F | 1 |
| Biondi-Zoccai, G | 1 |
| Frati, G | 1 |
| Palazzoni, G | 1 |
| Steingart, RM | 1 |
| Yadav, N | 1 |
| Manrique, C | 1 |
| Carver, JR | 1 |
| Liu, J | 1 |
| Lund, M | 1 |
| Alexandersson von Döbeln, G | 1 |
| Nilsson, M | 1 |
| Winter, R | 1 |
| Lundell, L | 1 |
| Tsai, JA | 1 |
| Kalman, S | 1 |
| Iskandar, MZ | 1 |
| Quasem, W | 1 |
| El-Omar, M | 1 |
| de Azambuja, E | 1 |
| Ameye, L | 1 |
| Diaz, M | 1 |
| Vandenbossche, S | 1 |
| Aftimos, P | 1 |
| Bejarano Hernández, S | 1 |
| Shih-Li, C | 1 |
| Delhaye, F | 1 |
| Focan, C | 1 |
| Cornez, N | 1 |
| Vindevoghel, A | 1 |
| Beauduin, M | 1 |
| Lemort, M | 1 |
| Paesmans, M | 1 |
| Suter, T | 1 |
| Piccart-Gebhart, M | 1 |
| Madeddu, C | 1 |
| Deidda, M | 1 |
| Piras, A | 1 |
| Cadeddu, C | 1 |
| Demurtas, L | 1 |
| Puzzoni, M | 1 |
| Piscopo, G | 1 |
| Scartozzi, M | 1 |
| Mercuro, G | 1 |
| Coccaro, M | 1 |
| Gallucci, G | 1 |
| Kinova, E | 1 |
| Zlatareva, N | 1 |
| Goudev, A | 1 |
| Dalzell, JR | 1 |
| Samuel, LM | 1 |
| Feola, M | 1 |
| Garrone, O | 1 |
| Occelli, M | 1 |
| Francini, A | 1 |
| Biggi, A | 1 |
| Visconti, G | 1 |
| Albrile, F | 1 |
| Bobbio, M | 1 |
| Merlano, M | 1 |
| Jensen, SA | 1 |
| Hasbak, P | 1 |
| Mortensen, J | 1 |
| Sørensen, JB | 1 |
| Sawaki, M | 1 |
| Mukai, H | 1 |
| Tokudome, N | 1 |
| Nakayama, T | 1 |
| Taira, N | 1 |
| Mizuno, T | 1 |
| Yamamoto, Y | 1 |
| Horio, A | 1 |
| Watanabe, T | 1 |
| Uemura, Y | 1 |
| Ohashi, Y | 1 |
| Bonneterre, J | 2 |
| Roché, H | 2 |
| Kerbrat, P | 2 |
| Fumoleau, P | 2 |
| Goudier, MJ | 2 |
| Fargeot, P | 2 |
| Montcuquet, P | 2 |
| Clavère, P | 1 |
| Barats, JC | 1 |
| Monnier, A | 2 |
| Veyret, C | 1 |
| Datchary, J | 1 |
| Van Praagh, I | 1 |
| Chapelle-Marcillac, I | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Widmer, L | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Romestaing, P | 1 |
| Namer, M | 1 |
| Luporsi, E | 1 |
| Roncalli, J | 1 |
| Delord, JP | 1 |
| Galinier, M | 1 |
| Massabuau, P | 1 |
| Lescure, M | 1 |
| Fauvel, JM | 1 |
| Azria, D | 1 |
| Ganz, PA | 1 |
| Hussey, MA | 1 |
| Moinpour, CM | 1 |
| Unger, JM | 1 |
| Hutchins, LF | 1 |
| Dakhil, SR | 2 |
| Giguere, JK | 1 |
| Goodwin, JW | 1 |
| Martino, S | 2 |
| Albain, KS | 1 |
| Perez, EA | 1 |
| Suman, VJ | 1 |
| Davidson, NE | 1 |
| Sledge, GW | 1 |
| Kaufman, PA | 1 |
| Hudis, CA | 1 |
| Gralow, JR | 1 |
| Ingle, JN | 1 |
| Winer, EP | 1 |
| Gelmon, KA | 1 |
| Gersh, BJ | 1 |
| Jaffe, AS | 1 |
| Rodeheffer, RJ | 1 |
| Kuropkat, C | 1 |
| Griem, K | 1 |
| Clark, J | 1 |
| Rodriguez, ER | 1 |
| Hutchinson, J | 1 |
| Taylor, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127] | Phase 2 | 181 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Identification of Chemo and Radiation Induced Systolic and Diastolic Myocardial Dysfunction in Patients With Cancer in Oesophagus and Gastroesophagael Junction - a Prospective Study[NCT03619317] | 56 participants (Anticipated) | Observational | 2018-06-25 | Recruiting | |||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)[NCT01554943] | Phase 2 | 73 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)[NCT02571894] | 320 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 22 |
| Chemotherapy | 7 |
Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 79 |
| Chemotherapy | 81 |
The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean global QoL | Dysphagia score all | |
| Chemotherapy | 69 | 31 |
| Radiochemotherapy | 67 | 27 |
5 reviews available for fluorouracil and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Chemotherapy-induced takotsubo cardiomyopathy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Echo | 2013 |
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cardiovascula | 2013 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorourac | 2016 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr | 2009 |
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Heart Diseases; Humans; Male; Tongu | 1999 |
8 trials available for fluorouracil and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2015 |
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2011 |
Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2008 |
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2008 |
8 other studies available for fluorouracil and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Acute reversible left ventricular systolic dysfunction associated with 5-fluorouracil therapy: a rare and increasingly recognised cardiotoxicity of a commonly used drug.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cardiotoxicity; Conservative Treatment; Diagnosis, D | 2019 |
Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel | 2013 |
5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection.
Topics: Adult; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Cardiotoxicity; Colonic Neoplasms; | 2015 |
Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2008 |
Right atrial thrombus from inferior vena cava after acute cardiotoxicity of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Echocardiography; Female; Fluorouracil; Heart Atria; Heart Diseases | 2008 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |